Clinical Efficacy of Arotinib Hydrochloride for Advanced Lung Squamous Cell Carcinoma
肖丹 1颜伟 1李君 2周壮发3
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 330029 江西省肿瘤医院
2. 330200 南昌大学第一附属医院
3. 334100 江西省上饶市广信区第二人民医院
折叠
摘要
目的 探讨盐酸安罗替尼维持治疗一线化疗后晚期肺鳞癌的疗效及安全性.方法 收集40例晚期肺鳞癌患者,已完成4～6个疗程标准化疗,应用随机抽签的方式将患者分为试验组及对照组,每一组20例患者,对照组给予最佳支持治疗,实验组给予安罗替尼维持治疗,比较两组PFS、血清VEGFR水平、KPS评分及安全性.结果 试验组和对照组的中位PFS分别为8.7个月和4.5个月(P＜0.05).维持治疗开始前试验组与对照组患者血清中血管内皮生长因子(VEGF)水平比较差异无统计学意义(P＞0.05),治疗后试验组患者血清中VEGF-2水平明显低于对照组(260.44±17.32 vs 320.15±19.04)pg/ml,P＜0.05).盐酸安罗替尼治疗后患者KPS评分基本维持在1分.患者不良反应轻,主要为高血压、手足综合征及黏膜溃疡,经治疗后均能缓解.结论 盐酸安罗替尼维持治疗一线化疗后病情稳定的晚期肺鳞癌患者,可提高PFS,维持较好的KPS评分,安全性好.
Abstract
Objective To explore the efficacy and safety of maintenance therapy with arotinib hydrochloride for ad-vanced lung squamous cell carcinoma after first-line chemotherapy.Methods 40 patients with advanced lung squamous cell car-cinoma who had completed 4～6 courses of standard chemotherapy were collected and randomly divided into the experimental group and the control group.Each group had 20 patients,and the control group received the best supportive treatment.The experi-mental group received maintenance treatment with arotinib.PFS,serum VEGFR levels,KPS scores,and safety were compared be-tween the 2 groups.Results The median PFS of the experimental group and the control group were 8.7 months(95％CI:6.7～11.0)and 4.5 months(95％CI:3.7～6.0),respectively(P＜0.05).Before the start of maintenance treatment,there was no statistically significant difference in the serum levels of vascular endothelial growth factor(VEGF)between the experimental group and the control group(P＞0.05).After treatment,the serum VEGF-2 levels in the experimental group were significantly lower than those in the control group(260.44±17.32 vs 320.15±19.04)pg/ml,P＜0.05).After treatment with arotinib hydrochlo-ride,the patient's KPS score remained basically at 1 point.The patient has mild adverse reactions,mainly hypertension,hand foot syndrome,and mucosal ulcers,which can be alleviated after treatment.Conclusion Anlotinib hydrochloride maintenance therapy can improve PFS,maintain a good KPS score,and have good safety in patients with advanced lung squamous cell carcinoma who have stable conditions after first-line chemotherapy.
维普
万方数据